GlassScriptPhysician profile
Joseph J Pachorek
NPI 1881622843
$6,464.78
in general payments reported to CMS, 2019-2025
36 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $496 · 2021: $667 · 2022: $1,883 · 2023: $1,141 · 2024: $999 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,068 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,067.62 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $1,248.00 | 2022 | |
| Abbvie INC. | $940.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $628.60 | 2022-2025 | |
| Amgen INC. | $524.60 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $420.45 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $294.09 | 2022-2025 | Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $282.24 | 2020-2025 | Nexletol |
| Idorsia Pharmaceuticals US INC | $279.74 | 2022-2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.54 | 2019-2023 | Trulance, Xifaxan |
| Pfizer INC. | $154.80 | 2019-2025 | |
| Amarin Pharma, INC. | $139.48 | 2019-2021 | |
| Glaxosmithkline, LLC. | $123.76 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $121.81 | 2024-2025 | Veozah |
| Allergan, INC. | $114.58 | 2020 | |
| Merck Sharp & Dohme LLC | $110.58 | 2021-2023 | Belsomra |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Pachorek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.